{"name":"Universidade Federal do Rio de Janeiro","slug":"universidade-federal-do-rio-de-janeiro","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"Melissa","genericName":"Melissa","slug":"melissa","indication":"Other","status":"marketed"},{"name":"cyclosporine and sodium carboximethycellulose","genericName":"cyclosporine and sodium carboximethycellulose","slug":"cyclosporine-and-sodium-carboximethycellulose","indication":"Other","status":"marketed"},{"name":"Melissa officinalis","genericName":"Melissa officinalis","slug":"melissa-officinalis","indication":"Other","status":"marketed"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"Phyt.decandra + Melissa offic.","genericName":"Phyt.decandra + Melissa offic.","slug":"phyt-decandra-melissa-offic","indication":"Phase 3 indication not publicly specified; likely immune or inflammatory condition based on constituent properties","status":"phase_3"},{"name":"Phytolacca decandra","genericName":"Phytolacca decandra","slug":"phytolacca-decandra","indication":"Lymphatic system support and immune stimulation (traditional/homeopathic use)","status":"marketed"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"Lopinavir/r","genericName":"Lopinavir/r","slug":"lopinavir-r","indication":"HIV-1 infection in treatment-naïve and treatment-experienced patients","status":"marketed"}]},{"name":"Ophthalmology","slug":"ophthalmology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"neuroscience","drugs":[{"name":"sodium carboximethycellulose","genericName":"sodium carboximethycellulose","slug":"sodium-carboximethycellulose","indication":"Dry eye syndrome (artificial tears)","status":"marketed"}]}],"pipeline":[{"name":"Melissa","genericName":"Melissa","slug":"melissa","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Phyt.decandra + Melissa offic.","genericName":"Phyt.decandra + Melissa offic.","slug":"phyt-decandra-melissa-offic","phase":"phase_3","mechanism":"A herbal combination of Phytolacca decandra and Melissa officinalis that likely exerts anti-inflammatory and immunomodulatory effects through polyphenolic and volatile oil constituents.","indications":["Phase 3 indication not publicly specified; likely immune or inflammatory condition based on constituent properties"],"catalyst":""},{"name":"Phytolacca decandra","genericName":"Phytolacca decandra","slug":"phytolacca-decandra","phase":"marketed","mechanism":"Phytolacca decandra (pokeweed) is a botanical preparation that stimulates immune function and has been traditionally used for its anti-inflammatory and lymphatic system-supporting properties.","indications":["Lymphatic system support and immune stimulation (traditional/homeopathic use)"],"catalyst":""},{"name":"cyclosporine and sodium carboximethycellulose","genericName":"cyclosporine and sodium carboximethycellulose","slug":"cyclosporine-and-sodium-carboximethycellulose","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Lopinavir/r","genericName":"Lopinavir/r","slug":"lopinavir-r","phase":"marketed","mechanism":"Lopinavir/ritonavir is a protease inhibitor combination that blocks HIV protease, preventing viral polyprotein cleavage and maturation.","indications":["HIV-1 infection in treatment-naïve and treatment-experienced patients","COVID-19 (investigational use in some settings)"],"catalyst":""},{"name":"Melissa officinalis","genericName":"Melissa officinalis","slug":"melissa-officinalis","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"sodium carboximethycellulose","genericName":"sodium carboximethycellulose","slug":"sodium-carboximethycellulose","phase":"marketed","mechanism":"Sodium carboxymethylcellulose is a cellulose derivative that acts as a viscous, water-soluble polymer to provide lubrication, moisture retention, and protective coating of mucosal surfaces.","indications":["Dry eye syndrome (artificial tears)","Oral mucositis protection","Gastrointestinal mucosal protection"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi0gFBVV95cUxPTGFEdWZMbWM4SU9FZ053Y0Jqd0hlaGlkVlQ0QWJJQTRvemk3YVV1Ql9welF3N2lHSGdRZDlFbk9aMUI0YW5aMUVYV0d3Y1R4TERRdnZLU0gzTWVJZkVNaDJKdERuSlgwcXd0dkZkTXFWTkZZWm1UbE9lSnUxZG5nZm81emc2ZjV4RnliSkZuYzNfNi1jRkp0YjIzYlJNbEhodXo4TFQtdFcyWEtXMzVsbDlpRTRseks5ZC1FSmdFMC1IUTNiVnZ3TGdoQzVraWRQVnc?oc=5","date":"2026-02-23","type":"pipeline","source":"NeoFeed","summary":"Cristália Laboratory prepares for a global leap with the drug that has enabled quadriplegics to walk - NeoFeed","headline":"Cristália Laboratory prepares for a global leap with the drug that has enabled quadriplegics to walk","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-01-05","type":"regulatory","source":"Folha de S.Paulo","summary":"First Stage of Testing for a Drug Targeting Complete Spinal Cord Injury Is Approved in Brazil - Folha de S.Paulo","headline":"First Stage of Testing for a Drug Targeting Complete Spinal Cord Injury Is Approved in Brazil","sentiment":"positive"},{"url":"https://news.google.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?oc=5","date":"2025-09-10","type":"pipeline","source":"Valor International","summary":"Cristália drug offers hope for quadriplegia patients - Valor International","headline":"Cristália drug offers hope for quadriplegia patients","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxQWTl2cHRKUDlUOG13UWZfaUEwanJ0QW1jelAzYjRGcFVmTVlYVWlrWmdvUE5KY3ZXSUQxdTAybE5WRjhPbmtiTkZmWWVlN1c5dVRUWENJSlc1cjFuOGtlVmw0Ul9FZWVxbXFnRkhVemJINllFM3BuX2NXSTRVblJuYjlvZG82MGFlTncyY0ZjcTh6d2M3eFZlUHhReFdaR0sxYWxFMnlreUhrTE9fWFRFUDB3?oc=5","date":"2024-06-05","type":"regulatory","source":"IPWatchdog.com","summary":"Brazilian Congress Debates Regulatory Data Protection for Pharmaceutical Products - IPWatchdog.com","headline":"Brazilian Congress Debates Regulatory Data Protection for Pharmaceutical Products","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxPREZoX25IM2F0dnNxQjN6eVhHajF1TnhEd3NrSTVzOUlZRUtRd3RGU0F6TXMyU0lvbkoxc0JtdDFSLWlpaUhmZUl2dU5HdXdXdGhja2lLbjVtcndXNkp4WGNmSlRsZmFQT0l2M0NjM1VsZ1F5NHUzX0NLLUVXTHkzSGd4ZENJUzFHWjQ5SWVnem5QOGpkdzc0Y0ZRdjlBVnd0dHUzZ09XTTVjRklSMXJkZ3FXVHc3UFJwcnNhb0dhTXB4R0k?oc=5","date":"2024-03-19","type":"trial","source":"Fierce Biotech","summary":"Crinetics pads case for oral hormone disorder drug, showing regulation of key biomarker in phase 3 - Fierce Biotech","headline":"Crinetics pads case for oral hormone disorder drug, showing regulation of key biomarker in phase 3","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxOaWR5UExnRmpic3JhRVB2SHNnR1BwbkJjRHMyOTNPT3E5OFgxWlBiSk5jSkRzaERmdmpHcmZheGJZS0pRRUFVQVBJZTlLUndCY2R0RzBwY1FRVEVYVlYyN0pwUkhsR3J1UGpQelphQjZmSWxGU0RwbWd5THptT2owWUdEYkVMV19GVnRhaVJnZkVtV1U?oc=5","date":"2024-02-10","type":"pipeline","source":"Frontiers","summary":"Medicinal Plants and Herbal Products From Brazil: How Can We Improve Quality? - Frontiers","headline":"Medicinal Plants and Herbal Products From Brazil: How Can We Improve Quality?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE9BUFB0ODJnSUlyU0VvMDhBRTJWYUtEUFB3UzRISDV4OGtuQTluX0tHUXd6aWFtRDdYNUhpU3RQajlPVkxvS3ZHRGgyQ3hrRWxBVmh6V2lUT2d1YUk3ZGRj?oc=5","date":"2023-11-03","type":"trial","source":"Science | AAAS","summary":"Copper drives prion protein phase separation and modulates aggregation - Science | AAAS","headline":"Copper drives prion protein phase separation and modulates aggregation - Science | AAAS","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxONEhMQTdGSDE4ck1XbkxqdEttNGlZLURadFZ1czVQNy1LYTFLQWpLY19rVTJuU014dVJubzVWZGFoZHJYY1UzLW92U2tHTG55dnVJSzNZSFdBVndTYkhqdWVnNFd3R29TRVhyXzJZQkVId1QzWE1LUHBKVjEzT1kzeWxKa3JmLUhhRGYxM3NpN2d5NlhHU1JVM3NsRUp6WTlQb0pFWGlhM01ENXpBY3VNQlI5Wi1hRVBqU1dZN2tiZVB0VGc?oc=5","date":"2022-09-05","type":"pipeline","source":"Latinoamérica 21","summary":"Lack of medicines in Brazil: a problem that comes from outside and meets with political inertia - Latinoamérica 21","headline":"Lack of medicines in Brazil: a problem that comes from outside and meets with political inertia - Latinoamérica 21","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibEFVX3lxTE1aVFo1eDg0MGM4LS00OXNHdHUxb0p3U3pfd0RVZ1RYR3BCc1VMWlFhT3lLOVpGWG9ZdW5YME1IR25kdUxQYkJGVDBvVHhwUGFQVWtpdHJzTGZTMDBKcEtvMk1XMVZ0QklVQ0RNbg?oc=5","date":"2022-02-11","type":"trial","source":"Wiley Online Library","summary":"Phase separation of the mammalian prion protein: Physiological and pathological perspectives - Wiley Online Library","headline":"Phase separation of the mammalian prion protein: Physiological and pathological perspectives","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMie0FVX3lxTE5pcEtVNEMzeHRPamFsWXdSa19Kc2Y5RUFnbzRGZ0tLNDJkamRkNlJya2pLeXhIMDFQbGc4RWNRVXhDVU9ObGs5bnRaY3g5aGhRYkxxYlhYdHo4eFhtaThGRFk4Nm1MdTdnLUxOX0hodWpmemNSeXV0RlAxWQ?oc=5","date":"2022-01-12","type":"pipeline","source":"Pharma Voice","summary":"The Researchers & Scientists - Pharma Voice","headline":"The Researchers & Scientists","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3AFBVV95cUxQS0xiUnhrbjlnQ19zcmJMMGI2STZVN2VCY2VobWs4enVkUTVkNXc0MGRhS2ZrUndjUXlGN2FxYmpfMzVjaHl3MlpPOEQ5ZGs0LTNXaTFPSXlrQ0xXeFZoamVfajhHN3g0OExoZ19LTjk4ZHZrVG03V3RKaE54bHRvSHhoYUotMmZzTWhBMzdKS29yalJKLXZnZ2pJQlFOeTdSU05vMXA1akkySXM5aFNUVWktTHNwc2RNbEpzU3YtcWg2V3JicllxWmVjZ2EtUll0NGkwWk5GUW9fbHFm?oc=5","date":"2018-09-13","type":"pipeline","source":"Intellectual Property Watch","summary":"Brazilian Supreme Court Refuses To Judge Its Biggest Case On IP And Access To Medicines, And Benefits Big Pharma With Undue Monopolies - Intellectual Property Watch","headline":"Brazilian Supreme Court Refuses To Judge Its Biggest Case On IP And Access To Medicines, And Benefits Big Pharma With Un","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE5qM2h5SFMtZXF6VXFmVHJVNzFyN0lPWUNwQ0FZamFrQTlGUm5yUDFwODI4VFI4S3RvWlAxRzY2ZXQ1WGFzZFJuQ3hrSVpMYS1TTDg4?oc=5","date":"2016-10-18","type":"pipeline","source":"Nature","summary":"Structural and haemostatic features of pharmaceutical heparins from different animal sources: challenges to define thresholds separating distinct drugs - Nature","headline":"Structural and haemostatic features of pharmaceutical heparins from different animal sources: challenges to define thres","sentiment":"neutral"}],"patents":[],"drugCount":7,"phaseCounts":{"marketed":6,"phase_3":1},"enrichmentLevel":2,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}